金吾财讯 | 国药控股(01099)公告，截至2025年6月30日止六个月，归属母公司持有者期内溢利为34.66亿元（人民币，下同），同比减少6.43%，每股基本盈利1.11元，去年同期为1.19元。不派中期息。期内，收入为2860.43亿元，同比减少2.95%。由于集团医药分销及器械分销业务收入下降所致。期内，集团医药分销收入为2185.27亿元，同比下降3.52%，占集团总收入比例为73.62%，其下降主要是由于带量采购、国谈品种降价等政策实施，市场竞争加剧，造成医药分销业务体量下降。期内，集团器械分销收入为570.53亿元，同比下降2.46%，占集团总收入比例为19.22%，其下降主要是由于带量采购政策实施的影响，毛利率较高的器械品类销售收入有所下降，以及受终端需求结构变化影响的医用耗材收入稳定增长。期内，集团医药零售收入为171.62亿元，同比上升3.65%，占集团总收入比例为5.78%，其上升主要是由于集团专业药房销售收入增长。期内，集团其他业务收入为40.76亿元，同比下降0.71%，主要是由于工业制品收入减少。期内，毛利为203.47亿元，同比减少7.28%。毛利率为7.11%，同比减少0.34个百分点。毛利下降主要是由于集团收入规模下降所致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.